Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL331350 | 0.95 | PDE5A (0.62) | PDE5AKCNH2 | |
| SCHEMBL331968 | 0.94 | PDE5A (0.56) | PDE5AKCNH2 | |
| SCHEMBL8296064 | 0.92 | PDE5A (0.56) | PDE5AKCNH2 | |
| SCHEMBL3389007 | 0.92 | PDE5A (0.63) | PDE5AKCNH2 | |
| SCHEMBL332461 | 0.91 | PDE5A (0.62) | PDE5AKCNH2 | |
| SCHEMBL4703201 | 0.91 | PDE5A (0.74) | PDE5AKCNH2 | |
| SCHEMBL8263482 | 0.91 | PDE5A (0.62) | PDE5AKCNH2 | |
| SCHEMBL331316 | 0.90 | PDE5A (0.52) | PDE5AKCNH2 | |
| SCHEMBL332823 | 0.90 | PDE5A (0.56) | PDE5AKCNH2 | |
| SCHEMBL332201 | 0.90 | PDE5A (0.52) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796288-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796287-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796287-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796288-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120214827-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214827-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120208830-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120208830-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-8227475-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227475-B2 | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PFIZER INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20070105877-A1 | Pyrazolopyrimidines | PFIZER INC | 2007-05-10 | — | — | US | disclosed |
| WO-2006120552-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE | PFIZER INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006120552-A2 | ANHYDROUS CRYSTALLINE FORMS OF N-[1-(2-ETHOXYETHYL)-5-(N-ETHYL-N-METHYLAMINO)-7-(4-METHYLPYRIDIN-2-yl-AMINO)-1H-PYRAZOLO[4,3-d]PYRIMIDINE-3-CARBONYL]METHANESULFONAMIDE | PFIZER INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006046135-A2 | PYRAZOLO[4,3-D] PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005097799-A1 | PYRAZOLO`4,3-D! PYRIMIDINES | PFIZER LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049617-A1 | PYRAZOLOPYRIMIDINES | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| WO-2004096810-A1 | 5,7-DIAMINOPYRAZOLO`4,3-D!PYRIMIDINES USEFUL IN THE TREATMENT OF HYPERTENSION | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
| US-20120214827-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PDE5A, PDE3A, PDE3B | PDE5A 1/4885KCNH2 446/4885 |
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | PDE5A 103/4885KCNH2 2253/4885 |
| US-20070105877-A1 | Pyrazolopyrimidines | DPYD, CYP2D6, TPMT | PDE5A 724/4885KCNH2 201/4885 |
| US-20120208830-A1 | Anhydrous Crystalline Forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide | PDE5A, PDE3A, PDE3B | PDE5A 1/4885KCNH2 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.